Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

NCT00543959 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

346

Enrollment

INDUSTRY

Sponsor class

Stopped This study is being discontinued based on data suggesting that none of the doses tested demonstrated both glycemic \& body fluid benefits vs. the comparitor

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG: MK0533
DRUG: Comparator: Placebo (unspecified)
DRUG: Comparator: pioglitazone

Sponsor

Merck Sharp & Dohme LLC